OA
Olukotun Adeoye y
Director
OFFICERM
Insider track record
ExecutiveNot enough buy signals with a settled T+90 horizon to measure a track record yet.
Browse the detailed record of transactions filed by Olukotun Adeoye y, Director. Officer active across 2 companies, notably Arrowhead Pharmaceuticals, INC.. In total, 15 filings have been recorded. Split: 0 buy · 9 sells. Total volume traded: €1.4m. History available since 13 September 2021. The latest transaction was disclosed on 18 August 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Olukotun Adeoye y
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations15 total
2,000 shares@ US$86.96Common StockSEC:0001242615-26-000002:0
3,090 shares@ US$66.700.0087% mcap21.8% of flowCommon StockSEC:0001242615-25-000006:0
6,083 shares@ US$68.0415.0% of flowCommon StockSEC:0001242615-25-000006:1
827 shares@ US$68.482.1% of flowCommon StockSEC:0001242615-25-000006:2
7,819 shares0Common StockSEC:0001242615-25-000004:0
0.812 shares@ US$1.91100.0% of flowCommon Stock, par value $0.001SEC:0001839882-25-012471:0
959 shares@ US$21.000.8% of flowCommon StockSEC:0001628280-25-002716:0
2,850 shares@ US$20.002.3% of flowCommon StockSEC:0001628280-24-052592:0
16,733 shares@ US$22.9915.6% of flowCommon StockSEC:0001628280-24-052273:0
14,987 shares@ US$25.4114.8% of flowCommon StockSEC:0001628280-23-041966:0
11,350 shares@ US$32.6514.9% of flowCommon StockSEC:0001209191-23-016446:0
7,867 shares0Common StockSEC:0001209191-23-003071:0
6,400 shares0Common StockSEC:0001209191-22-002593:0
1,890 shares@ US$64.265.5% of flowCommon StockSEC:0001209191-22-001328:0
2,250 shares@ US$63.766.3% of flowCommon StockSEC:0001209191-21-055966:0
About Olukotun Adeoye y
OLUKOTUN ADEOYE Y is a Director at Arrowhead Pharmaceuticals, INC. and Tonix Pharmaceuticals Holding Corp. He has 14 filings in total, and the 14 sampled filings, between 2021-09-14 and 2025-12-23, show 0 in purchases and 1228924 in sales, with the dominant transaction nature listed as Cession.